Program expansion: Covered entities purchased a record $66.3 billion in outpatient drugs under the 340B program in 2023, ...

Five companies account for 76.1% of the 340B contract pharmacy market, according to Drug Channels.  Since Congress established the 340B program in ...

Tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total community benefits in 2022. According to ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump ...

Republican lawmakers in the House have introduced a bill Tuesday that tightens eligibility and public reporting requirements within the 340B Drug Discount Program, earning the applause of industry ...

Amid ongoing controversy over 340B drug discounts, a sweeping review suggests the program is doing what it was intended to do: generate revenue for hospitals, clinics and pharmacies by requiring ...

The USA’s 340B hospital markup program is costing taxpayers an estimated $13.4 billion a year in lost Medicare rebates, according to a new report from Berkeley Research Group (BRG).

A recent report from the Congressional Budget Office found no evidence that savings from the 340B program are passed on to patients. Instead, the program may be encouraging behaviors that increase ...

The Kansas Legislature is currently considering a bill, SB 284, under seemingly noble pretense. Proponents of SB 284 argue ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...